Metastases with a Low PSA, What is PSA Doubling Time | Answering YouTube Comments #57 | PCRI
Metastases with a Low PSA, What is PSA Doubling Time | Answering YouTube Comments #57 | PCRI
|
Loading...
Lütfen bekleyiniz...
Type
Size

İlgili Videolar

Metastases with a Low PSA, What is PSA Doubling Time | Answering YouTube Comments #57 | PCRI

Metastases with a Low PSA, What is PSA Doubling Time | Answering YouTube Comments #57 | PCRI

|
PSA Less than 0.01 - Next Steps, Testosterone After Hormone Therapy | Answering YouTube Comments #58

PSA Less than 0.01 - Next Steps, Testosterone After Hormone Therapy | Answering YouTube Comments #58

|
Monitoring PSA After Radiation Therapy | Answering YouTube Comments #70 | Mark Scholz, MD | PCRI

Monitoring PSA After Radiation Therapy | Answering YouTube Comments #70 | Mark Scholz, MD | PCRI

|
What is Free PSA? | Answering YouTube Comments #18 | Mark Scholz, MD | PCRI

What is Free PSA? | Answering YouTube Comments #18 | Mark Scholz, MD | PCRI

|
Does a DRE or Biopsy Affect PSA, Does Erleada Affect PSA | Answering YouTube Comments #15 | PCRI

Does a DRE or Biopsy Affect PSA, Does Erleada Affect PSA | Answering YouTube Comments #15 | PCRI

|
Gleason 3+4 Active Surveillance, PSMA Alternatives, and More | Answering YouTube Comments #46 | PCRI

Gleason 3+4 Active Surveillance, PSMA Alternatives, and More | Answering YouTube Comments #46 | PCRI

|
Recurrent and Advanced Prostate Cancer | Answering Youtube Comments #5, The PCRI

Recurrent and Advanced Prostate Cancer | Answering Youtube Comments #5, The PCRI

|
Can You Be Diagnosed Without a Biopsy?, Zinc, and Chemo | Answering YouTube Comments #51

Can You Be Diagnosed Without a Biopsy?, Zinc, and Chemo | Answering YouTube Comments #51

|
Why ED Statistics are Misleading | Answering YouTube Comments #72 | Mark Scholz, MD | PCRI

Why ED Statistics are Misleading | Answering YouTube Comments #72 | Mark Scholz, MD | PCRI

|
PSMA After Recurrence, and PSMA Specificity | Answering YouTube Comments #26 | Mark Scholz, MD

PSMA After Recurrence, and PSMA Specificity | Answering YouTube Comments #26 | Mark Scholz, MD

|
What Is M0 Prostate Cancer and How Is It Identified? | Ask a Prostate Expert, Mark Scholz, MD

What Is M0 Prostate Cancer and How Is It Identified? | Ask a Prostate Expert, Mark Scholz, MD

|
Screening for Prostate Cancer with PSA | Prostate Cancer Staging Guide

Screening for Prostate Cancer with PSA | Prostate Cancer Staging Guide

|
Does Hormone Therapy Cause Cognitive Decline? | Answering YouTube Comments #62 | Mark Scholz, MD

Does Hormone Therapy Cause Cognitive Decline? | Answering YouTube Comments #62 | Mark Scholz, MD

|
Understanding PSA, PIRADS, Tumor Size, & Location | Answering YouTube Comments #59 | Mark Scholz, MD

Understanding PSA, PIRADS, Tumor Size, & Location | Answering YouTube Comments #59 | Mark Scholz, MD

|
Ep. 20 - Why An Increase in PSA Doubling Time is a Good Sign

Ep. 20 - Why An Increase in PSA Doubling Time is a Good Sign

|
PSA Recurrence: When Should You Treat? | Ask a Prostate Expert, Mark Scholz, MD

PSA Recurrence: When Should You Treat? | Ask a Prostate Expert, Mark Scholz, MD

|
Dairy & Prostate Cancer, Genomic Tests, and BPH Treatments | Answering YouTube Comments #55

Dairy & Prostate Cancer, Genomic Tests, and BPH Treatments | Answering YouTube Comments #55

|
Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRI

Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRI

|
Anemia, Robotic vs. Standard Surgery, Comparing Focal Therapies | Answering YouTube Comments #53

Anemia, Robotic vs. Standard Surgery, Comparing Focal Therapies | Answering YouTube Comments #53

|
Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13

Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13

|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa